FDA IND application for ST-01156 Ph 1 trial in patients with advanced solid tumor and heme malignances
“The FDA’s clearance of our IND for ST-01156 validates the power of SEED’s precision-engineered approach to protein degradation,” said Dr. Lan Huang, Co-Founder, Chairman, and CEO of SEED. “ST-01156 represents a fundamentally new class of medicines with many opportunities for impacting human health. Our near-term strategy is designed to explore several RBM39-dependent cancers, including Ewing sarcoma, neuroblastoma, and KRAS-driven solid tumors, an addressable patient population that exceeds one million worldwide.”
Share:
More News
“Initiation of the TEADCO Phase 1b/2 basket trial is another important milestone for the ODM-212 clinical development program and reflects our commitment to patients with difficult-to-treat cancers,” said Professor Outi Vaarala, Executive Vice President, Research & Development at Orion. “Together with the ongoing TEADES study, TEADCO highlights the versatility of
“In this study, tovecimig showed an impressive overall response rate which translated into a clinically meaningful and highly statistically significant improvement in PFS for patients with previously treated BTC. The remarkable 56% reduction in the risk of disease progression is unprecedented in this patient population without an actionable mutation in
“We are encouraged to see taletrectinib (IBTROZI) added to the NCCN Guidelines® for CNS Cancers given its demonstrated high rates of intracranial response that are durable in ROS1+ NSCLC patients with brain metastases,” said David Hung, M.D., Founder, President and Chief Executive Officer of Nuvation Bio. “Given the prevalence of
Daniel Getts, Ph.D., CEO of CREATE, added “MT-304 is proof of what our platform can do, and what our team can execute. Our mRNA-LNP leadership enables us to move from concept to clinic with remarkable speed. Just last weekend at AACR, we presented compelling preclinical data across our in vivo